Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBITDA Margin (2016 - 2025)

Macrogenics (MGNX) has disclosed EBITDA Margin for 14 consecutive years, with 34.27% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 431.0% to 34.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 49.89% through Dec 2025, down 885.0% year-over-year, with the annual reading at 49.89% for FY2025, 525.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 34.27% at Macrogenics, down from 23.11% in the prior quarter.
  • The five-year high for EBITDA Margin was 436.88% in Q2 2023, with the low at 1686.45% in Q2 2024.
  • Average EBITDA Margin over 5 years is 234.7%, with a median of 157.05% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -212334bps in 2024, then soared 152344bps in 2025.
  • Over 5 years, EBITDA Margin stood at 410.55% in 2021, then skyrocketed by 104bps to 17.66% in 2022, then plummeted by -2532bps to 429.51% in 2023, then surged by 91bps to 38.58% in 2024, then rose by 11bps to 34.27% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 34.27%, 23.11%, and 163.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.